Nancy L. Losben, RPh, CCP, FASCP, CG
Chief Quality Officer
Moorestown, New Jersey
Pharmacists: 1.0 Contact Hour (0.1 CEU)
Physicians: 1 Credit Hour
Nurses: 1 Contact Hour Medium
Chronic constipation is a common, costly, and burdensome condition, especially in the elderly, the depressed, and patients receiving long-term opioid pain-management therapy. Patients often self-medicate with multiple over-the-counter (OTC) products with minimal results and may develop tolerance to available therapies. Because these patients frequently find themselves seeking the aid of their physicians, pharmacists, and emergency medical services, health professionals should be prepared to discuss more effective strategies, including the use of newer pharmaceutical options.
Pharmacists, medical directors, other physicians, nurses, and other health care professionals caring for older adults.
Upon completion of this educational activity, the participant should be able to:
Identify the patient with chronic constipation
Conduct a medication therapy review to determine the possible medication-related causes of constipation and the efficacy of current drug therapy to treat chronic constipation
Develop a medication action plan for the patient with chronic constipation
Design an appropriate communication, documentation, and follow-up strategy to discuss the management of chronic constipation with patients and other health care providers
It is the policy of ASCP, in accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity.The intent of this disclosure is not to prevent an individual with significant financial interest or other relationship from serving as faculty, but rather to provide the participants with information with which they can make their own judgments. It remains for the participants to determine whether the facultyís interests or relationships may influence the activity with regard to exposition or conclusion. Nancy L. Losben, RPh, CCP, FASCP, CG, served as an advisory board member for Sucampo Pharmaceuticals, Inc., in 2007. This educational activity contains discussion of uses of drugs for the treatment of chronic constipation that are not approved by the Food and Drug Administration. Refer to the official prescribing information for each product for indications, contraindications, and warnings. AKH planners and reviewers have no relevant financial relationships to disclose.
Pharmacy Continuing Education: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program (ACPE #203-999-09-004-H01-P) is approved for 1.0 Contact Hour (0.1 CEU).
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc.AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensuratewith the extent of their participation in the activity.
NADONA/LTC is an approved provider of continuing nursing education by Georgia NursesAssociation, an accredited approver by theAmerican Nurses Credentialing Centerís Commission onAccreditation #1087.This program provides 1 contact hour by NADONA/LTC.
Commercial Support Statements
This activity is supported by an educational grant from Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. Certificate Fee